This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients
Annals of Hematology Open Access 15 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Haase D . Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515–526.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.
Löffler H, Rastetter J, Haferlach T . Atlas of Clinical Hematology, 6th edn Springer: Heidelberg, 2010.
Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et alMyelodysplastic syndromes In Jaffe ES, Harris N, Stein H, Vardiman J (eds). World Health Organization of Tumors, Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001; pp 61–73.
Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn IARC Press: Lyon, 2008; pp 87–93.
Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11–16.
McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121: 975–983.
Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, Campbell LJ et al. Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet 2011; 204: 603–628.
Sato Y, Suto Y, Pietenpol J, Golub TR, Gilliland DG, Davis EM et al. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 1995; 86: 1525–1533.
Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232–1237.
Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365–3373.
Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol 2012; 156: 67–75.
Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552–4560.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
WK, SS, TH and CH declare part ownership of the MLL Munich Leukemia Laboratory. SV, MZ, MS and JH are employed by the MLL Munich Leukemia Laboratory. All other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Volkert, S., Haferlach, T., Holzwarth, J. et al. Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions. Leukemia 30, 259–261 (2016). https://doi.org/10.1038/leu.2015.257
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.257
This article is cited by
-
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)
Leukemia (2022)
-
Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients
Annals of Hematology (2021)
-
Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome
Modern Pathology (2018)
-
Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance
Modern Pathology (2016)